Zacks Investment Research cut shares of Vital Therapies Inc (NASDAQ:VTL) from a hold rating to a sell rating in a research note issued to investors on Saturday.

According to Zacks, “Vital Therapies, Inc. is a biotherapeutic company. It is focused on developing a cell-based therapy targeting the treatment of acute liver failure. The Company operates in the United States, Europe, and China. Vital Therapies, Inc. is based in San Diego, California. “

Other equities research analysts have also recently issued reports about the stock. BTIG Research reaffirmed a hold rating on shares of Vital Therapies in a research note on Friday, March 10th. Canaccord Genuity set a $10.00 price target on shares of Vital Therapies and gave the stock a buy rating in a research note on Monday, January 2nd.

Shares of Vital Therapies (NASDAQ:VTL) traded down 1.39% on Friday, reaching $3.55. 41,680 shares of the company traded hands. Vital Therapies has a 1-year low of $3.50 and a 1-year high of $9.25. The stock’s market capitalization is $114.11 million. The company has a 50-day moving average of $4.07 and a 200-day moving average of $4.91.

Vital Therapies (NASDAQ:VTL) last released its quarterly earnings results on Tuesday, March 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by $0.01. During the same period in the prior year, the business earned ($0.34) EPS. Analysts anticipate that Vital Therapies will post ($1.51) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Marea Informative and is owned by of Marea Informative. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at

In other news, Director Muneer A. Satter acquired 3,750,000 shares of the company’s stock in a transaction dated Monday, March 27th. The shares were bought at an average price of $4.00 per share, for a total transaction of $15,000,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 29.88% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Sei Investments Co. bought a new stake in Vital Therapies during the third quarter worth $321,000. State Street Corp increased its stake in Vital Therapies by 6.0% in the fourth quarter. State Street Corp now owns 328,091 shares of the company’s stock worth $1,427,000 after buying an additional 18,645 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new stake in Vital Therapies during the third quarter worth $14,214,000. 26.68% of the stock is owned by institutional investors and hedge funds.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

5 Day Chart for NASDAQ:VTL

Get a free copy of the Zacks research report on Vital Therapies (VTL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for Vital Therapies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc and related stocks with our FREE daily email newsletter.